Friday, June 30, 2023 2:37:22 PM
NNVC has indeed received IND approval in India on 1/27/23 from DCGI.
https://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=67454&EncHid=&modid=&compid=%27,%2767454det%27
https://clinregs.niaid.nih.gov/country/india#
I'm not sure what this does to your hypothesis that you repeated over and over again here, something about "in all the history of ...., if someone hasn't gotten an IND in ... x ... years, they never have gotten one and never will," but I'd say it destroys it pretty well, in spite of the inane repetition of it. I guess someone had to be first biotech to be the longest one in preclinical development and a breaker of your "rule" / observation! I guess you were wrong with your prediction, despite dozens of repetitions of it over 7+ years. Being right for 7 years was pretty good, though!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=121988456
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170460706
Will see if they if they have any hint of decent results, if they will be able to attract a partner or raise funds to go it alone, and if they will be coming to the US and will get an IND here too.
P.S. Another company that raised over $100M and still in product development over ~2 decades plus is the private company, Brilliant Light Power. Will see if they start getting some traction this year too. They also have lots of doubters and detractors.
https://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=67454&EncHid=&modid=&compid=%27,%2767454det%27
https://clinregs.niaid.nih.gov/country/india#
I'm not sure what this does to your hypothesis that you repeated over and over again here, something about "in all the history of ...., if someone hasn't gotten an IND in ... x ... years, they never have gotten one and never will," but I'd say it destroys it pretty well, in spite of the inane repetition of it. I guess someone had to be first biotech to be the longest one in preclinical development and a breaker of your "rule" / observation! I guess you were wrong with your prediction, despite dozens of repetitions of it over 7+ years. Being right for 7 years was pretty good, though!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=121988456
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170460706
Will see if they if they have any hint of decent results, if they will be able to attract a partner or raise funds to go it alone, and if they will be coming to the US and will get an IND here too.
P.S. Another company that raised over $100M and still in product development over ~2 decades plus is the private company, Brilliant Light Power. Will see if they start getting some traction this year too. They also have lots of doubters and detractors.
Recent NNVC News
- In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides • ACCESS Newswire • 05/26/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 10:01:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:30:33 PM
- NanoViricides Announces Closing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/19/2026 03:55:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:45:22 PM
- Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides • ACCESS Newswire • 05/18/2026 12:30:00 PM
- NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/15/2026 12:35:00 PM
- NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II • ACCESS Newswire • 05/15/2026 12:00:00 PM
- Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides • ACCESS Newswire • 05/11/2026 12:30:00 PM
- NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference • Newsfile • 05/06/2026 07:37:00 PM
- NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
